Edgen Stock·Nov 30 2025, 02:40Back
BioAtla Reports 21.5-Month Median Survival in Refractory Sarcoma Trial for Mecbotamab Vedotin
Edgen Stock·Nov 30 2025, 02:40
[1] 523 Median OS of 21.5 months among 44 patients with treatment ... (https://www.researchgate.net/publication/3974 ...)[2] Mecbotamab Vedotin Shows Positive OS Results in Soft Tissue ... (https://www.cancernetwork.com/view/mecbotamab ...)[3] Sarcoma Alliance's post - Facebook (https://www.facebook.com/sarcomaalliance/post ...)
